Pharma Mar, S.A. (BME:PHM)

Market Cap	1.71B
Revenue (ttm)	167.00M
Net Income (ttm)	622.00K
Shares Out	17.41M
EPS (ttm)	0.03
PE Ratio	2,748.06
Forward PE	38.92
Dividend	0.65 (0.66%)
Ex-Dividend Date	Jun 12, 2024

Volume	42,150
Average Volume	64,094
Open	98.80
Previous Close	98.40
Day's Range	97.10 - 99.35
52-Week Range	26.16 - 103.00
Beta	-0.00
RSI	67.97
Earnings Date	Feb 28, 2025

About Pharma Mar

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung ca...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1986
• Employees: 509
• Stock Exchange: Madrid Stock Exchange
• Ticker Symbol: PHM

Financial Performance

In 2023, Pharma Mar's revenue was 158.15 million, a decrease of -19.45% compared to the previous year's 196.34 million. Earnings were 1.14 million, a decrease of -97.70%.